Efficacy and Safety of Low-Dose Blinatumomab in the Treatment of Refractory Autoimmune Encephalitis and Autoimmune Cerebellitis

by | Jul 6, 2026 | Clinical Trials | 0 comments

​ Conditions: Autoimmune Encephalitis (AE); Autoimmune Cerebellitis

Interventions: Drug: Blinatumomab

Sponsors: Beijing Tiantan Hospital

Not yet recruiting Conditions: Autoimmune Encephalitis (AE); Autoimmune Cerebellitis
Interventions: Drug: Blinatumomab
Sponsors: Beijing Tiantan Hospital
Not yet recruiting 

Submit a Comment

Your email address will not be published. Required fields are marked *